Laurus is adopting a product-specific approach instead of market-specific strategies.

Laurus Labs steps up focus on R&D with a pipeline of 60 products

Laurus Labs delivered a miss on Q4 earnings, led by a sharp decline in the Synthesis (CDMO) business. Motilal Oswal Securities expects FY24 to be a year of consolidation for Laurus Labs in terms of sales.

Laurus Labs shares plunge 10% in afternoon trade, slip below Rs 300 level

Shares of Coforge would turn ex-dividend today. Coforge had announced an interim dividend of Rs 19 per share and the record date for the same is today. The dividend will be paid on May 26.

Laurus Labs, Coforge shares to turn ex-dividend; L&T, Gujarat Gas Q4 results today

Buzzing stocks: Laurus Labs, Bharti Airtel, Godrej Consumer, Mukund, ABB India, Adani Wilmar, Anupam Rasayan India, Bajaj Consumer Care, Cholamandalam Investment, Godrej Properties, Havells India, Reliance Power, Sula Vineyards, Tata Chemicals, Titan Company, Vimta Labs and Vishnu Chemicals

Stocks to watch on May 3, 2023

Laurus Labs has received U.S. FDA’s tentative approval for paediatric antiretroviral drug Dolutegravir 5mg and 10mg in oral dispersible film (ODF) dosage form.

U.S. FDA gives tentative nod for Laurus’ paediatric ARV oral dispersible film drug

Laurus Labs closes 1.3 percent higher at Rs 311.60, with volumes of 45.5 lakh shares. The stock has gained 6 percent in two sessions

Laurus Labs shares extend gains on USFDA approval for HIV drug

Sharekhan recommended Hold rating on Laurus Labs with a target price of Rs 338 in its research report dated April 28, 2023.

Hold Laurus Labs; target of Rs 338: Sharekhan

Based on the OI percentage, 83 stocks, including Aarti Industries, Syngene International, IndiaMART InterMESH, Laurus Labs, and IDFC First Bank, saw long build-ups.

Trade setup for today: Top 15 things to know before the opening bell

Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 340 in its research report dated April 27, 2023.

Buy Laurus Labs; target of Rs 340 : Motilal Oswal

The drugmaker’s net profit was down 55% year-on-year to Rs 103 crore in the quarter ended March, as per an exchange filing.

Laurus Labs Q4 Results Review: Brokerages Cut Estimates On Uncertain FY24 Outlook

‘Expect #FY24 to be a year of consolidation’ says Satyanarayana Chava of Laurus Labs. Tells Prashant Nair, Nigel D'Souza & Reema Tendulkar that they expect to reach margin of 25% in FY24.

#lauruslabs #lauruslabshare #cnbctv18 #businessnews  #businessnewstoday #businessnewsinenglish #sharemarkettoday  

About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here. 

You can also connect with CNBC-TV18 News Online
Catch the latest news: https://bit.ly/2YbpXBM

Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/

Stay updated with all the market action in real time: https://www.cnbctv18.com/market-live/

You can also stay updated with all the latest news on-the-go with CNBC-TV18 Minis: https://www.cnbctv18.com/minis/

n18oc_business

Laurus Labs' Satyanarayana Chava On Q4FY23 Results, Growth Outlook & More | CNBC-TV18

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Ltd